In particular, Hirakawa et al. showed that low-dose of IL-2 induce STAT5 activation in Helios+ Treg cell and CD56brightCD16– NK cells in vitro and the selective expansion of these cell subsets was observed in GVHD patients upon IL-2 treatment [184]. The gene discussed is IL2; the disease is graft versus host disease.